Geode Capital Management LLC Trims Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Geode Capital Management LLC decreased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,193,505 shares of the biopharmaceutical company's stock after selling 11,723 shares during the quarter. Geode Capital Management LLC owned 2.05% of TG Therapeutics worth $96,145,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of TGTX. HighTower Advisors LLC lifted its holdings in shares of TG Therapeutics by 19.6% during the 3rd quarter. HighTower Advisors LLC now owns 12,526 shares of the biopharmaceutical company's stock valued at $294,000 after buying an additional 2,053 shares during the last quarter. State Street Corp lifted its holdings in shares of TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock worth $212,712,000 after buying an additional 2,398,015 shares during the last quarter. Wellington Management Group LLP grew its position in TG Therapeutics by 12.7% in the 3rd quarter. Wellington Management Group LLP now owns 73,320 shares of the biopharmaceutical company's stock worth $1,715,000 after purchasing an additional 8,249 shares during the last quarter. Barclays PLC increased its stake in TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after acquiring an additional 158,323 shares during the period. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in shares of TG Therapeutics during the third quarter valued at approximately $1,039,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Price Performance

Shares of TGTX traded down $0.31 during trading hours on Wednesday, reaching $38.72. The stock had a trading volume of 270,285 shares, compared to its average volume of 3,099,597. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a market capitalization of $6.08 billion, a PE ratio of -387.95 and a beta of 2.14. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32. The company's 50-day moving average is $35.98 and its two-hundred day moving average is $31.60.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. Research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.